Search
Avanafil
go.drugbank.com/drugs/DB06237Approved[L32113] It first received FDA approval on April 27, 2012,[L32058] with subsequent EMA approval in June 2013.[L32113]
Cangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalCangrelor was approved by the FDA in June 2015 for intravenous application.
Donidalorsen
go.drugbank.com/drugs/DB18751ApprovedInvestigational[L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783]
Synonyms: -(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL), DNA, D((2'-O-(2-METHOXYETHYL))M5RU-SP-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RA-SP-G-SP-T-SP-M5C-SP-T-SP-M5C-SP-T-SP-T-SP-G-SP-G-SP-M5C-SPTimolol
go.drugbank.com/drugs/DB00373ApprovedInvestigational[L6727] Timolol was first approved by the FDA in 1978.
Potassium chloride
go.drugbank.com/drugs/DB00761ApprovedInvestigationalWithdrawnThe FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release
Ranolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigationalIt was originally approved by the FDA in 2006.[L5440]
Diethylstilbestrol
go.drugbank.com/drugs/DB00255ApprovedWithdrawn(Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigational[A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]
Durlobactam
go.drugbank.com/drugs/DB16704ApprovedInvestigational[L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023.
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation. … [L46133] Continual FDA approval is contingent on clinical benefits from ongoing trials, particularly the Phase 3 ATLAST study in people with presymptomatic SOD1-ALS.
Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP